SCHEDULE 13G/A: Macquarie Group Discloses 5.41% Stake in Travere Therapeutics

Macquarie Group Limited and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 5.41% in Travere Therapeutics Inc. common shares as of March 31, 2025.

Summary

• Macquarie Group Limited, Macquarie Management Holdings Inc., and Macquarie Investment Management Business Trust jointly filed an Amendment No. 5 to Schedule 13G.
• The filing reports beneficial ownership of 4,797,314 common shares of Travere Therapeutics Inc.
• This represents 5.41% of the total class of securities outstanding.
• The event date requiring this filing was March 31, 2025.
• Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust hold sole voting and sole dispositive power over all 4,797,314 shares.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual report of beneficial ownership, which is neutral in sentiment. The presence of a significant institutional investor could be seen as mildly positive, but the filing itself is purely informational.

Positives

• A significant institutional investor, Macquarie Group, holds a substantial stake (5.41%) in Travere Therapeutics, indicating their investment interest.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates that a major global financial services group, Macquarie, maintains a significant passive investment in Travere Therapeutics, a biotechnology company. Such institutional holdings are common and reflect investment strategies rather than active corporate control intentions, as certified by the filers.

Stakeholder Impact

• Shareholders: The filing informs existing and potential shareholders about a significant institutional investor's stake, which can influence market perception and liquidity.

Key Dates

Keywords

Travere Therapeutics Inc, Macquarie Group Limited, Macquarie Management Holdings Inc, Macquarie Investment Management Business Trust, Schedule 13G, Beneficial Ownership, Common Shares, Institutional Investor, SEC Filing, TRVR